Pediatrix CEO sells 23,000 shares, retains 302,805 shares

Pediatrix Medical Group, Inc. disclosed that its chief executive officer, who also serves as a director, sold 23,000 shares of Pediatrix common stock on December 15, 2025.

Rhea-AI Filing Summary

Pediatrix Medical Group, Inc. disclosed that its chief executive officer, who also serves as a director, sold 23,000 shares of Pediatrix common stock on December 15, 2025. The shares were sold at a weighted average price of $22.41 per share, with individual sale prices ranging from $22.00 to $22.62.

After completing this transaction, the insider directly beneficially owned 302,805 shares of Pediatrix common stock. The sale was reported as a disposition of non-derivative securities held directly by the reporting person.

Insider Trade Summary

Net Seller: 23,000 shares

Net Sell 1 txn

Insider ORDAN MARK S

Role Chief Executive Officer

Sold 23,000 shs ($515K)

Type	Security	Shares	Price	Value
Sale	Common Stock	23,000	$22.41	$515K

Holdings After Transaction: Common Stock — 302,805 shares (Direct)

Footnotes (1)

1. F1. The price in Colum 4 is a weighted average price. The reported securities were sold in multiple transactions with prices ranging from $22.00 to $22.62 for a weighted average sales price of $22.41. The reporting person undertakes to provide the issuer, any security holder of the issuer of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each seperate price within the range set forth in this footnote.

FAQ

What insider transaction did Pediatrix Medical Group (MD) report?

Pediatrix Medical Group reported that its chief executive officer and director sold 23,000 shares of the company’s common stock on December 15, 2025.

At what price were the Pediatrix (MD) shares sold in this insider transaction?

The 23,000 shares were sold at a weighted average price of $22.41 per share, with individual prices ranging from $22.00 to $22.62.

How many Pediatrix shares does the insider own after the reported sale?

Following the sale, the reporting person directly beneficially owned 302,805 shares of Pediatrix Medical Group common stock.

What is the role of the reporting person in Pediatrix Medical Group (MD)?

The reporting person is both a director and the chief executive officer of Pediatrix Medical Group, Inc.

Were any derivative securities reported in this Pediatrix insider filing?

The filing includes a table for derivative securities, but only the non-derivative transaction involving 23,000 shares of common stock was reported in the provided content.

How was the sale price of Pediatrix (MD) shares described in the insider report?

The sale price was described as a weighted average price of $22.41 per share, based on multiple transactions between $22.00 and $22.62.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/17/2025 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ORDAN MARK S

(Last) (First) (Middle)

1301 CONCORD TERRACE

(Street)

SUNRISE FL 33323

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Pediatrix Medical Group, Inc. [ MD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/15/2025		S		23,000	D	$22.41(1)	302,805	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price in Colum 4 is a weighted average price. The reported securities were sold in multiple transactions with prices ranging from $22.00 to $22.62 for a weighted average sales price of $22.41. The reporting person undertakes to provide the issuer, any security holder of the issuer of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each seperate price within the range set forth in this footnote.

Remarks:

See Exhibit 24.1 - Power of Attorney

	/s/ Mary Ann E. Moore, Attorney-in-Fact	12/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.